Find and Pitch Jounalists, Get Your Story Covered

Tags: osimertinib amivantamab egfr inhibitor lung cancer liquid

	Profile	Recent Articles on Subject
1	Crystal Phend MedPage Today Contributing editor at MedPage Today. Personal views. HealthcareEditing	SGLT2i Improves Outcomes After TAVI - 12 days ago Weight-Loss Drug Benefit Spans HFpEF, HFmrEF - over 1 year ago
2	Kristen Monaco MedPage Today	SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease - about 2 months ago Complement Inhibitor Shows Promise for Rare Kidney Disorder - 5 months ago Interim ALIGN Data: Atrasentan Cuts Proteinuria in IgA Nephropathy - 5 months ago Alternative Pathway Inhibition Makes Good in IgA Nephropathy - 6 months ago Once-Rejected Drug Now FDA Approved for CKD-Related Anemia - about 1 year ago One Class of Antidiabetic Linked With Lower Kidney Stone Risk - about 1 year ago In Acute Kidney Disease, SGLT2 inhibitors Were All-Around Protective - over 1 year ago Quick Albuminuria Reduction Key Factor in Finerenone's Efficacy - over 1 year ago Sparsentan Bests Irbesartan for Preserving Kidney Function in IgA Nephropathy - over 1 year ago Sparsentan Failed to Preserve Kidney Function Over Time in FSGS - over 1 year ago FDA Approves First Phosphate Absorption Inhibitor for CKD - over 1 year ago FDA Approves Another SGLT2 Inhibitor for Treating CKD - over 1 year ago
3	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	EC approves Rybrevant with Lazcluze for advanced lung cancer - 3 months ago Everest therapy shows promise in nephropathy trial - 4 months ago MHRA grants approval for bladder cancer drug erdafitinib - 5 months ago Amgen’s trial brings new hope for IgG4-RD patients - 10 months ago
4	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about unsupported drug price hikes, an annual HIV prevention shot, and more - 4 months ago STAT+: Pharmalittle: Novo halts Ozempic kidney failure trial after early signs of success; GSK settles California Zantac lawsuit - over 1 year ago
5	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Novel BTK Inhibitor Succeeds in Heavily Pretreated Immune Thrombocytopenia - 4 months ago FDA OKs Amivantamab as First-Line Lung Cancer Treatment - about 1 year ago New Oral Drug Approved for Metastatic Colorectal Cancer - over 1 year ago New Options Challenge Standard Treatments in EGFR-Mutant NSCLC - over 1 year ago Randomized Trial Backs HIF-2a Inhibition in Advanced RCC - over 1 year ago
6	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Antibody Drug Conjugate Targeting CLDN1 Receives FDA Fast Track Designation - 5 months ago Zaltenibart Receives FDA Rare Pediatric Disease Designation for C3 Glomerulopathy - 6 months ago Adagrasib Meets Primary Endpoint Among Individuals with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC - about 1 year ago
7	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	FDA Panel Rejects SGLT1/2 Inhibitor for Type 1 Diabetes - 5 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 7 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 8 months ago FDA Approves Belzutifan for Advanced Renal Cell Carcinoma - over 1 year ago Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations - over 1 year ago Novel Drug Makes Its Case for Pretreated Primary Biliary Cholangitis - over 1 year ago RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer - over 1 year ago
8	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Exploratory Analysis Shows Favorable Outcomes for Amivantamab-Lazertinib Treatment in NSCLC - 7 months ago FDA Grants Accelerated Approval for Elafibranor as Treatment of Primary Biliary Cholangitis - 10 months ago FDA Approves Sotatercept-csrk for Pulmonary Arterial Hypertension - about 1 year ago FDA Grants Orphan Drug Designation to Felzartamab for Kidney Transplant Recipients - about 1 year ago FLOW Trial Results Demonstrate Positive Kidney Outcomes With Semaglutide - about 1 year ago FDA Approves Osimertinib With Chemotherapy for EGFRm NSCLC - about 1 year ago FDA Approves Enfortumab Vedotin, Pembrolizumab for Treatment of Urothelial Cancer - over 1 year ago FDA Approves Belzutifan for Treatment of Advanced Renal Cell Carcinoma - over 1 year ago FDA Grants Breakthrough Therapy Designation to Novel Drug for Progressive Pulmonary Fibrosis - over 1 year ago FDA Approves Empagliflozin for Adults With Chronic Kidney Disease at Risk of Progression - over 1 year ago FDA Grants Priority Review to New Drug Application for Belzutifan for Advanced Renal Cell Carcinoma - over 1 year ago
9	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Axatilimab-csfr for cGVHD - 8 months ago
10	Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. PoliticsStorytellingCats	Empagliflozin Shows 10% Relative Risk Reduction in Time to First Hospitalization Due to Heart Failure - about 1 year ago

Journalists covering egfr inhibitor